Testosterone Therapy and Prostate Cancer: Incorporating Low-Level Evidence into Practical Recommendations
Abstract
The widely accepted absolute contraindication for administration of testosterone in hypogonadal men with prostate cancer has been questioned. Although recommendations from some professional associations still adhere to the traditional concepts, there is increasing relaxation of such positions. Currently, the evidence for definitive guidelines is unavailable and the clinician has to rely on incomplete but best attainable information. Under certain circumstances (successfully treated prostate cancer or active surveillance for low risk disease), testosterone administration is warranted. For those with intermediate or high-risk cancer, extreme caution seems advisable. The benefits must heavily outweigh the hazards. Ideally, these men should participate in clinical trials and registries. Competent initial assessment of individual circumstances and follow-up are mandatory.
Read the paper
Related studies
- Induced osteoblast differentiation by amide derivatives of stilbene: The possible osteogenic agents
- On model selections for repeated measurement data in clinical studies
- Regulation of GLUT transporters by flavonoids in androgen-sensitive and -insensitive prostate cancer cells
- Region-specific microRNA signatures in the human epididymis
- Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety
- In Vitro characterization of the endocrine disrupting effects of per- and poly-fluoroalkyl substances (PFASs) on the human androgen receptor
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.